This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer
- PET/CT-Derived Whole-Body and Bone Marrow Dosimetry of 89Zr-Cetuximab
- Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging
- Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma
- Mass Scaling of S Values for Blood-Based Estimation of Red Marrow Absorbed Dose: The Quest for an Appropriate Method
- Linear Regression Model for Predicting Patient-Specific Total Skeletal Spongiosa Volume for Use in Molecular Radiotherapy Dosimetry
- Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults With Recurrent High-Grade Glioma
- Blood-Based Red Marrow Dosimetry: Where's the Beef?
- Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131-Labeled Murine Anti-CD30 Monoclonal Antibody
- Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma
- Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion Protein in Patients with Gastrointestinal Malignancies
- Dosimetry of Internal Emitters
- Bone Marrow Dosimetry Using Blood-Based Models for Radiolabeled Antibody Therapy: A Multiinstitutional Comparison
- Dosimetric Analysis of Radioimmunotherapy with 186Re-Labeled Bivatuzumab in Patients with Head and Neck Cancer
- Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid (DOTA)-Peptide versus 2IT-DOTA Monoclonal Antibody Linkage for RIT
- Final Results of a Phase I Radioimmunotherapy Trial Using 186Re-Epratuzumab for the Treatment of Patients with Non-Hodgkin's Lymphoma
- Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma
- Reinfusion of Unprocessed, Granulocyte Colony-stimulating Factor-stimulated Whole Blood Allows Dose Escalation of 186Relabeled Chimeric Monoclonal Antibody U36 Radioimmunotherapy in a Phase I Dose Escalation Study
- Improved Prediction of Myelotoxicity Using a Patient-Specific Imaging Dose Estimate for Non-Marrow-Targeting 90Y-Antibody Therapy
- Evaluation of Limited Blood Sampling in a Preceding 99mTc-Labeled Diagnostic Study to Predict the Pharmacokinetics and Myelotoxicity of 186Re-cMAb U36 Radioimmunotherapy
- Patient Dosimetry of Intravenously Administered 99mTc-Annexin V
- Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck